<!DOCTYPE html><html xmlns="http://www.w3.org/1999/xhtml" xmlns:epub="http://www.idpf.org/2007/ops" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd">
<head>

<meta http-equiv="default-style" content="text/html; charset=utf-8" />
<title>Campbell-Walsh-Wein Urology Twelfth Edition Review</title>
<link rel="stylesheet" type="text/css" href="../../style/Elsevier_eBook.css" />
<link rel="stylesheet" type="text/css" media="only screen" href="../../style/media.css" />
  

<link rel="stylesheet" type="text/css" href="../../widgets/common_assets/css/common.css" />
<link rel="stylesheet" type="text/css" href="../../widgets/common_assets/css/variables.css" />
<script type="text/javascript" src="../../widgets/common_assets/scripts/mathjax/tex-mml-chtml.js"></script>
<script type="text/javascript" src="../../widgets/common_assets/scripts/common.js"></script>
<script type="text/javascript" src="../../widgets/img_lightbox_handler/img_lightbox_data.js"></script>
<script type="text/javascript" src="../../widgets/img_lightbox_handler/img_lightbox_parent.js"></script>
</head>
<body>
<section epub:type="chapter">
<a id="c0097"></a>
<header>
<div id="CN">97</div>
<h1 class="chaptitle" epub:type="title" id="B9780323639699000975">Malignant Renal Tumors</h1>
<address>
<div class="chapau" id="augrp0010">Steven C. Campbell, Brian R. Lane,, and Philip M. Pierorazio</div>
</address>
</header>
<section>
<h3 class="h2hd" id="cesectitle0010">Keywords</h3>
<div class="keywords">active surveillance; checkpoint inhibitors; chronic kidney disease; partial nephrectomy; radical nephrectomy; renal cell carcinoma; renal mass; thermal ablation; tyrosine kinase inhibitors</div>
</section>
<section>
<section>
<a id="s0010"></a>
<h2 class="h1hd" id="cesectitle0015">Questions</h2>
<div id="p0010"></div>
<div>
    <iframe src="../../widgets/MCMS/xhtml/ch097_assessments.xhtml" height="700"></iframe>

    


</div><div>

<div class="boxg1" id="b0010">
<p></p>
<div class="b1title" epub:type="title" id="title5050">Chapter review</div>
<div id="bpar0010"></div>
<div>
<ul class="ce_list" id="olist0400">
<li class="b1numlist" id="bpar0015">
<a id="o2535"></a>1. A solid mass on CT scan that enhances more than 15 Hounsfield units is suggestive of RCC.</li>
<li class="b1numlist" id="bpar0020">
<a id="o2540"></a>2. Twenty percent of small solid enhancing masses less than 4 cm on CT are benign, 40% of small solid enhancing masses less than 2 cm on CT are benign.</li>
<li class="b1numlist" id="bpar0025">
<a id="o2545"></a>3. Hyperdense cysts (Bosniak II) contain old blood and are benign.</li>
<li class="b1numlist" id="bpar0030">
<a id="o2550"></a>4. Clear cell RCCs originate from the proximal tubule; oncocytomas and chromophobe RCCs originate from the distal tubule.</li>
<li class="b1numlist" id="bpar0035">
<a id="o2555"></a>5. There is ample evidence for impaired immune surveillance in RCC.</li>
<li class="b1numlist" id="bpar0040">
<a id="o2560"></a>6. Bilateral involvement in RCC either synchronously or metachronously occurs in 2% to 4% of patients.</li>
<li class="b1numlist" id="bpar0045">
<a id="o2565"></a>7. RCC pathologically is classified as clear cell: 70% to 80%; papillary: 10% to 15%; chromophobe: 3% to 5%; collecting duct: less than 1%; and medullary: rare.</li>
<li class="b1numlist" id="bpar0050">
<a id="o2570"></a>8. Alterations in chromosome 3 are common in clear cell renal carcinoma.</li>
<li class="b1numlist" id="bpar0055">
<a id="o2575"></a>9. Papillary renal cell cancer has a tendency to multifocality.</li>
<li class="b1numlista" id="bpar0060">
<a id="o2580"></a>10. Paraneoplastic syndromes include hypercalcemia, hypertension, polycythemia, and hepatic dysfunction (Stauffer syndrome).</li>
<li class="b1numlista" id="bpar0065">
<a id="o2585"></a>11. Stauffer syndrome is a paraneoplastic syndrome associated with RCC that results in elevated liver function tests. If hepatic function does not normalize after nephrectomy, persistent hepatic dysfunction is indicative of persistent disease.</li>
<li class="b1numlista" id="bpar0070">
<a id="o2590"></a>12. Enlarged perirenal lymph nodes noted on CT may be inflammatory, particularly if they are less than 2 cm in diameter. Lymph nodes larger than 2 cm generally contain metastases.</li>
<li class="b1numlista" id="bpar0075">
<a id="o2595"></a>13. Extended lymphadenectomy for renal cell carcinoma has not been shown to be beneficial for the majority of patients over conventional lymphadenectomy, which includes the renal hilar and adjacent paracaval or para-aortic lymph nodes.</li>
<li class="b1numlista" id="bpar0080">
<a id="o2600"></a>14. The World Health Organization and International Society of Urologic Pathology (ISUP) grading system from 1 to 4 is used to grade the renal tumor and is based on nuclear characteristics.</li>
<li class="b1numlista" id="bpar0085">
<a id="o2605"></a>15. There is an increased incidence of renal cell carcinoma in patients with acquired renal cystic disease.</li>
<li class="b1numlista" id="bpar0090">
<a id="o2610"></a>16. RCC involving the vena cava that infiltrates the wall of the vena cava has an extremely poor prognosis.</li>
<li class="b1numlista" id="bpar0095">
<a id="o2615"></a>17. A patient with a tumor thrombus involving the vena cava associated with metastatic regional nodal disease has a very poor prognosis.</li>
<li class="b1numlista" id="bpar0100">
<a id="o2620"></a>18. A patient with a tumor thrombus involving the vena cava in which the nodes are negative and there is no invasion of the vein wall (except the ostia) has a relatively good prognosis.</li>
<li class="b1numlista" id="bpar0105">
<a id="o2625"></a>19. Ipsilateral adrenalectomy as part of a radical nephrectomy is not necessary unless there is CT evidence of adrenal involvement, contiguous spread of the tumor to the adrenal, or large upper pole renal masses that are adjacent to with concern for involvement of the adrenal gland.</li>
<li class="b1numlista" id="bpar0110">
<a id="o2630"></a>20. The risk for developing recurrent malignant disease is greatest in the first 3 years after surgery.</li>
<li class="b1numlista" id="bpar0115">
<a id="o2635"></a>21. In a partial nephrectomy, the amount of renal parenchyma taken with the tumor does not affect oncologic outcomes provided the margin itself is negative.</li>
<li class="b1numlista" id="bpar0120">
<a id="o2640"></a>22. RCCs less than 3.5 cm in general grow less than 0.5 cm per year; some may grow up to 1 cm per year.</li>
<li class="b1numlista" id="bpar0125">
<a id="o2645"></a>23. Incomplete excision of a large primary tumor or debulking is rarely indicated as a sole treatment for patients with metastatic kidney cancer.</li>
<li class="b1numlista" id="bpar0130">
<a id="o2650"></a>24. Sarcomas typically have a pseudocapsule that cannot be relied on for a plane of dissection because microscopic tumor will be left behind.</li>
<li class="b1numlista" id="bpar0135">
<a id="o2655"></a>25. Metastatic tumors to the kidney are common, appearing in 12% of patients who die of other cancers; the most common primary lesions are those of the lung, breast, or gastrointestinal tract, melanoma, or hematologic.</li>
<li class="b1numlista" id="bpar0140">
<a id="o2660"></a>26. Major poor prognostic indicators include tumors that extend beyond Gerota fascia to involve contiguous organs (pT4), have lymph node involvement (N1), or are metastatic (M1).</li>
<li class="b1numlista" id="bpar0145">
<a id="o2665"></a>27. Patients with von Hippel-Lindau disease should have all tumors in a kidney treated when the largest reaches 3 cm in size.</li>
<li class="b1numlista" id="bpar0150">
<a id="o2670"></a>28. Patients with a significant reduction in renal mass are at risk for developing long-term renal functional impairment from hyperfiltration renal injury. These patients should have their urinary protein excretion monitored because proteinuria is the initial manifestation of hyperfiltration injury.</li>
<li class="b1numlista" id="bpar0155">
<a id="o2675"></a>29. Established critical prerequisites for successful cryosurgery include rapid freezing, gradual thawing, and a repetition of the freeze-thaw cycle.</li>
<li class="b1numlista" id="bpar0160">
<a id="o2680"></a>30. Approximately 20% of angiomyolipomas are found in patients with the tuberous sclerosis (TS) syndrome, an autosomal dominant disorder characterized by mental retardation, epilepsy, and adenoma sebaceum, a distinctive skin lesion. TS, similar to VHL, is transmitted in an autosomal dominant manner.</li>
<li class="b1numlista" id="bpar0165">
<a id="o2685"></a>31. Cystic nephromas are benign renal neoplasms that occur most commonly in middle-aged women.</li>
<li class="b1numlista" id="bpar0170">
<a id="o2690"></a>32. The VHL syndrome’s major manifestations can include the development of renal cell carcinoma, pheochromocytoma, retinal angiomas, and hemangioblastomas of the brain stem, cerebellum, or spinal cord.</li>
<li class="b1numlista" id="bpar0175">
<a id="o2695"></a>33. Inactivation or mutation of the VHL gene leads to dysregulated expression of hypoxia inducible factor, an intracellular protein that plays an important role in regulating cellular responses to hypoxia, starvation, and other stresses. This in turn leads to a several-fold upregulation of the expression of vascular endothelial growth factor (VEGF).</li>
<li class="b1numlista" id="bpar0180">
<a id="o2700"></a>34. Hereditary papillary renal cell carcinoma has an autosomal dominant mode of transmission.</li>
<li class="b1numlista" id="bpar0185">
<a id="o2705"></a>35. Chromosome 3 alterations and VHL mutations are common in clear renal cell carcinoma, and mutation or inactivation of this gene (VHL) has been found in over 75% of sporadic cases.</li>
<li class="b1numlista" id="bpar0190">
<a id="o2710"></a>36. Renal medullary carcinoma is a rare histologic subtype of RCC that occurs almost exclusively in association with sickle cell trait.</li>
<li class="b1numlista" id="bpar0195">
<a id="o2715"></a>37. Most collecting duct carcinomas are centrally located and exhibit an infiltrative growth pattern and aggressive clinical course.</li>
<li class="b1numlista" id="bpar0200">
<a id="o2720"></a>38. Direct ipsilateral adrenal involvement is now grouped with other RCCs that extend beyond Gerota fascia as pathologic stage T4 (pT4).</li>
</ul>
</div>
</div>

</div>
</section>
<footer>
<section epub:type="footnotes">
<div class="ftnote">
<hr />
<p class="ftnote1" id="fn1" epub:type="footnote">
<sup>
<a href="#cfn1">a</a><span id="cfn1"></span>
</sup> <a id="ntpara0010"></a>Sources referenced can be found in <span class="italic">Campbell-Walsh Urology, 11th Edition,</span> on the Expert Consult website.</p>
</div>
<div class="pageavoid">
<figure class="fig" id="f0010">
<img src="../../IMAGES/B9780323639699000975/main.assets/f97-01-9780323639699.jpg" alt="image"/>
<figcaption class='figleg'>
<span class="fignum">Fig. 97.1</span>
</figcaption>
</figure>
</div>

<div class="pageavoid">
<figure class="fig" id="f0016">
<img src="../../IMAGES/B9780323639699000975/main.assets/f97-02-9780323639699.jpg" alt="image"/>
<figcaption class='figleg'>
<span class="fignum">Fig. 97.2</span>
<br/>
<span class="figcredit">From Bostwick DG, Cheng L: <span class="italic">Urologic surgical pathology</span>, 2nd ed, Edinburgh, 2008, Mosby.</span>
</figcaption>
</figure>
</div>

<div class="pageavoid">
<figure class="fig" id="f0021">
<img src="../../IMAGES/B9780323639699000975/main.assets/f97-03-9780323639699.jpg" alt="image"/>
<figcaption class='figleg'>
<span class="fignum">Fig. 97.3</span>
<br/>
<span class="figcredit">From Bostwick DG, Cheng L. <span class="italic">Urologic surgical pathology,</span> 2nd ed, Edinburgh, 2008, Mosby.</span>
</figcaption>
</figure>
</div>

<div class="pageavoid">
<figure class="fig" id="f0026">
<img src="../../IMAGES/B9780323639699000975/main.assets/f97-04-9780323639699.jpg" alt="image"/>
<figcaption class='figleg'>
<span class="fignum">Fig. 97.4</span>
</figcaption>
</figure>
</div>

<div class="pageavoid">
<figure class="fig" id="f0031">
<img src="../../IMAGES/B9780323639699000975/main.assets/f97-05-9780323639699.jpg" alt="image"/>
<figcaption class='figleg'>
<span class="fignum">Fig. 97.5</span>
</figcaption>
</figure>
</div>

<div class="pageavoid">
<figure class="fig" id="f0036">
<img src="../../IMAGES/B9780323639699000975/main.assets/f97-06-9780323639699.jpg" alt="image"/>
<figcaption class='figleg'>
<span class="fignum">Fig. 97.6</span>
</figcaption>
</figure>
</div>
</section>
</footer>
</section>
</section><span id="s0015"></span><span id="s0025"></span><span id="f0011"></span><span id="f0015"></span><span id="f0020"></span><span id="f0025"></span><span id="f0030"></span><span id="f0035"></span><span id="pagebreak_373"></span><span id="pagebreak_374"></span><span id="pagebreak_375"></span><span id="pagebreak_376"></span><span id="pagebreak_377"></span> <span id="pagebreak_378"></span><span id="pagebreak_379"></span><span id="pagebreak_380"></span>
<span id="pagebreak_381"></span><span id="pagebreak_382"></span><span id="pagebreak_383"></span>
</body>
</html>
